Prostate cancer

Cover Page

Cite item

Full Text

Abstract

Prostate cancer (RPP) is a malignant neoplasm that arises from the epithelium of the prostate gland gland (PJ).

Thethiology and pathogenesis of this disease remain poorly studied. Many studies are aimed at studying diet, food, hormonal impact, as well as infections in the etiology of the RLPG. The prevalence of RPL depends on ethnic and geographical features. The highest incidence of African Americans living in the United States (60% higher than that of white Americans), the least high - in the Chinese living in China [1]. In addition to racial features, the risk factors of the RPG are considering the genetic predisposition, the age of men and nutritional features. The probability of developing a PJ tumor in a man who has one of the closest relatives of the first degree of kinship (father or brother) sick of the RLPG, is 1.8 times higher than in the population. If two relatives were sick or more (father and brother or both brothers), the risk of RPG increases in 5.51 and 7.71 times, respectively [2, 3]. African Americans have an increased risk of identifying RPG, as well as a greater probability of detecting aggressive RPG [4]. Also, the risk of RLPG is rising in men who use a large amount of animal fats [5].

About the authors

Andrei D. Kaprin

National Medical Research Center of Radiology; People’s Friendship University of Russia (RUDN University)

Email: lbolotina@yandex.ru
ORCID iD: 0000-0001-8784-8415

D. Sci. (Med.), Prof., Acad. RAS

Russian Federation, Moscow; Moscow

Boris Ia. Alekseev

National Medical Research Center of Radiology

Email: lbolotina@yandex.ru

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Vsevolod B. Matveev

Blokhin National Medical Research Center of Oncology

Email: lbolotina@yandex.ru

D. Sci. (Med.), Prof., Corr. Memb. RAS

Russian Federation, Moscow

Dmitrii Iu. Pushkar’

Yevdokimov Moscow State University of Medicine and Dentistry

Email: lbolotina@yandex.ru

D. Sci. (Med.), Prof., Corr. Memb. RAS

Russian Federation, Moscow

Aleksandr V. Govorov

Yevdokimov Moscow State University of Medicine and Dentistry

Email: lbolotina@yandex.ru
ORCID iD: 0000-0003-3299-0574

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Nina A. Gorban’

Central Clinical Hospital with a Polyclinic

Email: lbolotina@yandex.ru

Cand. Sci. (Med.)

Moscow

Andrei A. Kirichek

Gaaz Moscow Medical and Social Institute; Moscow City Oncological Hospital №62

Email: lbolotina@yandex.ru

Assistant

Russian Federation, Moscow; Moscow

Vitalii A. Biriukov

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

Cand. Sci. (Med.)

Russian Federation, Obninsk

Mariia I. Volkova

Blokhin National Medical Research Center of Oncology

Email: lbolotina@yandex.ru

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Igor A. Gulidov

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

department head

Russian Federation, Obninsk

Iuliia V. Gumenetskaia

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

D. Sci. (Med.)

Russian Federation, Obninsk

Valerii V. Krylov

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

D. Sci. (Med.)

Russian Federation, Obninsk

Oleg B. Kariakin

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

D. Sci. (Med.)

Russian Federation, Obninsk

Aleksei A. Krasheninnikov

Herzen Moscow Scientific Research Institute of Oncology – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

Research Assistant

Russian Federation, Moscow

Iurii S. Mardynskii

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

Corr. Memb. RAS

Russian Federation, Obninsk

Kirill M. Niushko

Herzen Moscow Scientific Research Institute of Oncology – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

Cand. Sci. (Med.)

Russian Federation, Moscow

Tatiana I. Zakharova

Blokhin National Medical Research Center of Oncology

Email: lbolotina@yandex.ru

Cand. Sci. (Med.)

Russian Federation, Moscow

Andrei A. Kostin

National Medical Research Center of Radiology

Email: lbolotina@yandex.ru

deputy general director

Russian Federation, Moscow

Evgenii V. Khmelevskii

Herzen Moscow Scientific Research Institute of Oncology – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

department head

Russian Federation, Moscow

Aleksandr A. Fedenko

Herzen Moscow Scientific Research Institute of Oncology – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

D. Sci. (Med.)

Russian Federation, Moscow

Larisa V. Bolotina

Herzen Moscow Scientific Research Institute of Oncology – branch of the National Medical Research Center for Radiology

Author for correspondence.
Email: lbolotina@yandex.ru
ORCID iD: 0000-0003-4879-2687

D. Sci. (Med.)

Russian Federation, Moscow

Natalia A. Falaleeva

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

D. Sci. (Med.)

Russian Federation, Obninsk

Elena V. Filonenko

Herzen Moscow Scientific Research Institute of Oncology – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

D. Sci. (Med.), Prof., department head

Russian Federation, Moscow

Aleksei A. Nevol’skikh

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

D. Sci. (Med.)

Russian Federation, Obninsk

Sergei A. Ivanov

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

D. Sci. (Med.), Prof. RAS

Russian Federation, Obninsk

Zhanna V. Khailova

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: lbolotina@yandex.ru

Cand. Sci. (Med.)

Russian Federation, Obninsk

Tigran G. Gevorkian

Blokhin National Medical Research Center of Oncology

Email: lbolotina@yandex.ru

deputy director

Russian Federation, Moscow

References

  1. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973–1995. SEER Program, National Cancer Institute, NIH Pub.; 99–4543, Bethesda: MD, 1999.
  2. Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate. 1990;17:337-437.
  3. Stewart RW, et al. Screening for prostate cancer. Semin Oncol. 2017;44:47.
  4. Tan DS, et al. Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. J Clin Oncol. 2016;34:91.
  5. Denis L, Morton MS, Griffiths K. Diet and its preventive role in prostatic disease. Eur Urol. 1999;35:377-87.
  6. Jansson KF, et al. Concordance of tumor differentiation among brothers with prostate cancer. Eur Urol. 2012;62:656.
  7. Key TJ. Nutrition, hormones and prostate cancer risk: results from the European prospective investigation into cancer and nutrition. Recent Results Cancer Res. 2014;202:39.
  8. Alexander DD, et al. Meta-Analysis of Long-Chain Omega-3 Polyunsaturated Fatty Acids (LComega-3PUFA) and Prostate Cancer. Nutr Cancer. 2015;67:543.
  9. Lippi G, et al. Fried food and prostate cancer risk: systematic review and meta-analysis. Int J Food Sci Nutr. 2015;66:587.
  10. Chen P, et al. Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015;94:e1260.
  11. Ilic D, et al. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas. 2012;72:269.
  12. Bylsma LC, et al. A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer. Nutr J. 2015;14:125.
  13. Kristal AR, et al. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014;23:1494.
  14. Nyame YA, et al. Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. J Clin Oncol. 2016;34:1345.
  15. Lippman SM, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39.
  16. Kramer BS, et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol. 2009;27:1502.
  17. Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192.
  18. Thompson IM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215.
  19. Haider A, et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median follow up of 3 registries. J Urol. 2015;193:80.
  20. Zhou CK, et al. Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 2016;183:210.
  21. Lian WQ, et al. Gonorrhea and Prostate Cancer Incidence: An Updated Meta-Analysis of 21 Epidemiologic Studies. Med Sci Monit. 2015;21:1902.
  22. Rao D, et al. Does night-shift work increase the risk of prostate cancer? А systematic review and meta-analysis. Onco Targets Ther. 2015;8:2817.
  23. Raslau D, et al. The risk of prostate cancer in pilots: a meta-analysis. Aerosp Med Hum Perform. 2015;86:112.
  24. Islami F, et al. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol. 2014;66:1054.
  25. Zhang XL, et al. Vasectomy and the risk of prostate cancer: a meta-analysis of cohort studies. Int J Clin Exp Med. 2015;8:17977.
  26. Huang TB, et al. Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol. 2014;46:1715.
  27. Bhindi B, et al. The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy. Urology. 2014;84:1073.
  28. Lin SW, et al. Prospective study of ultraviolet radiation exposure and risk of cancer in the United States. Int J Cancer. 2012;131:E1015.
  29. Pabalan N, et al. Association of male circumcision with risk of prostate cancer: a meta-analysis. Prostate Cancer Prostatic Dis. 2015;18:352.
  30. Rider JR, et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016;70:974.
  31. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018 Jan 8. pii: a030361. doi: 10.1101/cshperspect.a030361
  32. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2019 [Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. AD Kaprin, VV Starinsky, GV Petrova. Moscow, 2019 (in Russian)].
  33. Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2019 [The state of cancer care for the population of Russia in 2018. Ed. AD Kaprin, VV Starinsky, GV Petrova. Moscow, 2019 (in Russian)].
  34. Partin AW, Kattan MW, Subong ENP, et al. Combination of prostatespecific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA. 1997;227:1445-51.
  35. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-4.
  36. Partin AW, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843.
  37. Gosselaar C, et al. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol. 2008;54:581.
  38. Алексеева Г.Н., Гурина Л.И., Писарева Л.Ф., Рознер В.Э. Сравнительная характеристика диагностической значимости методов обследования пациентов с подозрением на злокачественные новообразования предстательной железы. Тихоокеанский медицинский журнал. 2011;3:48-50 [Alekseeva GN, Gurina LI, Pisareva LF, Rozner VE. Sravnitel’naia kharakteristika diagnosticheskoi znachimosti metodov obsledovaniia patsientov s podozreniem na zlokachestvennye novoobrazovaniia predstatel’noi zhelezy. Tikhookeanskii meditsinskii zhurnal. 2011;3:48-50 (in Russian)].
  39. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40(2):244-52. doi: 10.1097/PAS.0000000000000530
  40. Pedersen KV, Carlson P, Varenhorst E, et al. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ. 1990;300:1041-4.
  41. Chodak GW. Early detection and screening for prostatic cancer. Urology. 1989;34(Suppl.4):10-2.
  42. Thompson IM, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004;350:2239.
  43. Carlsson S, et al. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study. Eur Urol. 2017;71:46.
  44. Albright F, et al. Prostate cancer risk prediction based on complete prostate cancer family history. Prostate. 2015;75:390.
  45. Ilic D, et al. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1.
  46. Loeb S, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015;193(4):1163-9.
  47. Hamoen EHJ, et al. Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta-analysis. Eur Urol. 2015;67(6):1112-21.
  48. Crawford ED, Schutz MJ, Clejan S, et al. The effect of digital rectal examination on prostatespecific antigen levels. JAMA. 1992;267:2227-8.
  49. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate specific antigen in a community based population of healthy men: establishment of age specific reference ranges. JAMA. 1993;270:860-4.
  50. Edwards JE, Moore RA. Finasteride in the treatment of clinical benignprostatic hyperplasia: A systematic review of randomized trials. BMC Urol. 2002;2:14.
  51. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol. 1994;151:1283-90.
  52. Lodding P, Aus G, Bergdahl S, et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml prostate specific antigen. J Urol. 1998;159:899-903.
  53. Dong F, et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol. 2008;180:150.
  54. Loeb S, et al. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol. 2015;67:619.
  55. Benson MC, Olsson CA. Prostate specific antigen density – roles in patient evaluation and management. Cancer. 1994;74:1667-73.
  56. Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate specific antigen of the transition zone: a new parameter for prostate cancer prediction. J Urol. 1997;157:1315-21.
  57. Catalona WJ, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542.
  58. Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent free PSA, PSA density and age specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56(2):255-60.
  59. Carter HB, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215.
  60. Catalona WJ, Beiser JA, Smith DS. Serum free prostatespecific antigen and prostatespecific antigen density measurements for predicning cancer in men with prior negative prostatic biopsies. J Urol. 1997;158:2162-7.
  61. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;19:3352-9.
  62. Partin AW, Kattan MW, Subong ENP, et al. Combination of prostatespecific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA. 1997;227:1445-51.
  63. Smith JA, Lange RA, Janknegt RA, et al. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol. 1997;157:1329-34.
  64. Heidenreich A. Identification of high-risk prostate cancer: role of prostate-specific antigen, PSA doubling time, and PSA velocity. Eur Urol. 2008;54:976.
  65. O’Brie MF, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol. 2009;27:3591.
  66. Vickers AJ, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009;27:398.
  67. Deras IL, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587.
  68. Hessels D, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8.
  69. Nakanishi H, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179:1804.
  70. Luo Y, et al. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis. Chin Med J (Engl). 2014;127(9):1768-74.
  71. Hessels D, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 2010;70:10.
  72. De la Calle C, et al. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men. J Urol. 2015;194:65.
  73. Catalona WJ, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185:1650.
  74. Loeb S, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015;193(4):1163-9.
  75. Liu Y, et al. Prostate health index in predicting the results of prostate biopsy for prostate cancer: a meta-analysis. Zhonghua Nan Ke Xue. 2014;20(8):723-9.
  76. Haese A, Graefen M, Steuber T, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate. 2001;49(2):101-9.
  77. Auprich M, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol. 2011;60:1045.
  78. Wolff JM, Ittel TH, Borchers H, et al. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase. Anticancer Res. 1999;19:2653-5.
  79. Lee F, Torp-Pedersen ST, Siders DB, et al. Transrectal ultrasound in the diagnosis and staging of prostate cancer. Radiology. 1989;170:609-15.
  80. Wang R, et al. Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients. Clin Cancer Res. 2017;23:3692.
  81. Available at: https://uroweb.org/guideline/prostate-cancer/#note_158
  82. Song JM, et al. Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: a meta-analysis for this diagnostic triad of prostate cancer in symptomatic Korean men. Yonsei Med J. 2005;46(3):414-24.
  83. Bryant RJ, Sjoberg DD, Vickers AJ, et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst. 2015;107(7).
  84. Митина Л.А., Казакевич В.И., Степанов С.О. Ультразвуковая онкоурология. М.: Триумф, 2009 [Mitina LA, Kazakevich VI, Stepanov SO. Ultrasound urology oncology. Moscow: Triumph, 2009 (in Russian)].
  85. Ellis WJ, Chetner MР, Preston SD, Brawer MK. Diagnosis of prostatecarcinoma: the yield of serum prostate specific antigen, digital restal examination, and transrectal ultrasonography. J Urol. 1994;152:1520-5.
  86. Patel U, Rickards D. The diagnostic value of colour Doppler flow in the peripheral zone of the prostate, with histological correlation. Br J Urol. 1994;74(5):590-5.
  87. Smeenge M, et al. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int. 2012;110:942.
  88. Bratan F, et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol. 2013;23:2019.
  89. Le JD, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015;67:569.
  90. Borofsky S, et al. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology. 2018;286:186.
  91. Zhang L, et al. A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. Eur Radiol. 2017;27(12):5204-14.
  92. Smith JAJr, et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol. 1997;157:902.
  93. Mitterberger M, et al. The value of three-dimensional transrectal ultrasonography in staging prostate cancer. BJU Int. 2007;100:47.
  94. Sauvain JL, et al. Value of power doppler and 3D vascular sonography as a method for diagnosis and staging of prostate cancer. Eur Urol. 2003;44:21.
  95. Schnall MD, Imai Y, Tomaszewski J, et al. Prostate cancer: local staging with endorectal surface coil MR imaging. Radiology. 1991;178:797-802.
  96. De Rooij M, et al. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. Eur Urol. 2016;70:233.
  97. Jager GJ, et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol. 1996;166:845.
  98. Mohler JL, Srinivas S, Antonarakis ES, et al. Prostate cancer. In: NCCN Guidelines Version 4. 2019.
  99. Harisinghani MG, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491.
  100. Hovels AM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387.
  101. Eifler JB, et al. Pelvic lymph node dissection is associated with symptomatic venous thromboembolism risk during laparoscopic radical prostatectomy. J Urol. 2011;185(5):1661-6.
  102. Heck MM, et al. Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2014;41:694.
  103. Budiharto T, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol. 2011;60:125.
  104. Van Leeuwen PJ, et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int. 2017;119:209.
  105. Briganti A, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol. 2010;57:551.
  106. Abuzallouf S, et al. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171:2122.
  107. Shen G, et al. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014;43(11):1503-13.
  108. Shariat SF, et al. Using biopsy to detect prostate cancer. Rev Urol. 2008;10:262.
  109. Xue J, et al. Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis. Oncotarget. 2017;8:23322.
  110. Moldovan P, et al. Accuracy of Elastic Fusion of Prostate Magnetic Resonance and Transrectal Ultrasound Images under Routine Conditions: A Prospective Multi-Operator Study. PLoS One. 2016;11:e0169120.
  111. Eichler K, et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175:1605.
  112. Pelzer AE, et al. Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening project. Eur Urol. 2005;48:916.
  113. Davis M, Sofer M, Kim SS, Soloway MS. The procedure of transrectalultrasound guided biopsy of the prostate: a survey of patient preparation and biopsy technique. J Urol. 2002;167(2;Pt.1):566-70.
  114. Roberts MJ, et al. Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. Urology. 2017;104:11.
  115. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: A randomized controlled study. BJU Int. 2000;85(6):682-5.
  116. Grabe M, Bartoletti R, Bjerklund‐Johansen TE, et al. Guidelines on urological infections. Eur Assoc Urol. 2015;p.50-8.
  117. Wolf JSJr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. Am Urol Assoc. 2014;p.1-45.
  118. Yasuda M, Nakane K, Yamada Y, et al. Clinical effectiveness and safety of tazobactam/piperacillin 4.5 g for the prevention of febrile infectious complication after prostate biopsy. J Infect Chemother. 2014;20:631-4.
  119. Pepdjonovic L, et al. Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis. World J Urol. 2017;35:1199.
  120. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int. 2000;85:682-5.
  121. Knobloch R, et al. Bilateral fine-needle administered local anaesthetic nerve block for pain control during TRUS-guided multi-core prostate biopsy: a prospective randomised trial. Eur Urol. 2002;41:508.
  122. Alavi AS, Soloway MS, Vaidya A, et al. Local anesthesia for ultrasound guided prostate biopsy: A prospective randomized trial comparing 2 methods. J Urol. 2001;166(4):1343-5.
  123. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 1994;151(6):1571-4.
  124. Richie JP, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology. 1993;42:365.
  125. Carvalhal GF, et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol. 1999;161:835.
  126. Ericson KJ, et al. Prostate cancer detection following diagnosis of atypical small acinar proliferation. Can J Urol. 2017;24:8714.
  127. Epstein JI, et al. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006;175:820.
  128. Merrimen JL, et al. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol. 2009;182:485.
  129. Kronz JD, et al. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy. Hum Pathol. 2001;32:389.
  130. Guo CC, et al. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol. 2006;19:1528.
  131. Walz J, et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol. 2006;50:498.
  132. Moran BJ, et al. Re-biopsy of the prostate using a stereotactic transperineal technique. J Urol. 2006;176:1376.
  133. Cornud F, et al. Precision Matters in MR Imaging-targeted Prostate Biopsies: Evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies. Radiology. 2018;287:534.
  134. Hegarty J, et al. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev. 2010;11.
  135. Linzer DG, et al. Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer. Urology. 1996;48:757.
  136. Zigeuner R, et al. Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. Urology. 2003;62:883.
  137. Link RE, Morton RA. Indications for pelvic lymphadenectomy in prostate cancer. Urol Clin North Am. 2001;28(3):491-8.
  138. Fossati N, et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. 2017;72:84.
  139. Mattei A, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol. 2008;53:118.
  140. Studer UE, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol. 2008;53:941.
  141. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate cancer v.2.2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
  142. De Bono, et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from> 4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Ann Oncol. 2019;30:v328-v329.
  143. Chodak GW, Thisted RA, Gerber GS. Results of conservative management of clinically localized prostate cancer. N Eng J Med. 1994;330:242-8.
  144. Lu-Yao GL, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202.
  145. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975-80.
  146. Wilt TJ, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017;377:132.
  147. Lundgren R, Nordle O, Josefsson K. Immediate estrogen or estramustinephosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: A randomized multicenter study with 15 years of follow-up. The South Sweden Prostate Cancer Study Group. J Urol. 1995;153:1580-6.
  148. Boustead G, Edwards SJ. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta‐analysis of randomized controlled trials. BJU Int. 2007;99(6):1383-9.
  149. Bruinsma SM, et al. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer – results of a modified Delphi consensus procedure. Nat Rev Urol. 2017;14:312.
  150. Jayadevappa R, et al. Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis (PRISMA Compliant). Medicine. 2017;96:18.
  151. Mahran A, et al. Younger Men With Prostate Cancer Have Lower Risk of Upgrading While on Active Surveillance: A Meta-analysis and Systematic Review of the Literature. Urology. 2018;121:11-8.
  152. Simpkin AJ, et al. Systematic review and meta-analysis of factors determining change to radical treatment in active surveillance for localized prostate cancer. Eur Urol. 2015;67(6):993-1005.
  153. Tosoian JJ, et al. Intermediate and Longer-Term Outcomes From a Prospective Active- Surveillance Program for Favorable-Risk Prostate Cancer. J Clin Oncol. 2015;33:3379.
  154. Albertsen PC. Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol. 2015;25:232.
  155. Bill-Axelson A, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer – 29-Year Follow-up. N Engl J Med. 2018;379:2319.
  156. Wilt TJ, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017;377:132.
  157. Hamdy FC, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;375:1415.
  158. Yaxley JW, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet. 2016;388:1057.
  159. Coughlin GD, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncol. 2018;19:1051.
  160. Adolfsson J, et al. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity. Eur Urol. 2007;52:1028.
  161. Jonsson E, et al. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Scand J Urol Nephrol. 2006;40:265.
  162. Lu-Yao GL, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202.
  163. Albertsen PC, et al. Statistical considerations when assessing outcomes following treatment for prostate cancer. J Urol. 1999;162:439.
  164. Iversen P, et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol. 2004;172(5 Pt 1):1871-6.
  165. Briganti A, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61:480.
  166. Gandaglia G, et al. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. Eur Urol. 2017;72:632.
  167. Cimino S, et al. Comparison between Briganti, Partin and MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis. Scand J Urol. 2017;51:345.
  168. Roach M. 3rd et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28:33.
  169. Dell’Oglio P, et al. External validation of the European association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy. J Endourol. 2014;28:416.
  170. Hinev AI, et al. Validation of nomograms predicting lymph node involvement in patients with prostate cancer undergoing extended pelvic lymph node dissection. Urol Int. 2014;92(3):300-5.
  171. Wit EMK, et al. Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy. Eur Urol. 2017;71:596.
  172. Van der Poel HG, et al. Sentinel node biopsy for prostate cancer: report from a consensus panel meeting. BJU Int. 2017;20(2):204-11.
  173. Bader P, et al. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol. 2002;168:514.
  174. Passoni NM, et al. Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis. BJU Int. 2014;114:503.
  175. Steuber T, et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol. 2006;175:939.
  176. Zorn KC, et al. External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy. J Endourol. 2007;21:1345.
  177. Rud E, et al. Does preoperative magnetic resonance imaging reduce the rate of positive surgical margins at radical prostatectomy in a randomised clinical trial? Eur Urol. 2015;68:487.
  178. Engel J, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010;57:754.
  179. Kumar S, et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006:CD006019.
  180. Shelley MD, et al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35(1):9-17.
  181. Ramsay C, et al. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technol Assess. 2012;16:1.
  182. Burkhard FC, et al. The role of lymphadenectomy in prostate cancer. Nat Clin Pract Urol. 2005;2:336.
  183. Davis JW, et al. Robot-assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient selection needs. BJU Int. 2011;108:993.
  184. Briganti A, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol. 2006;50:1006.
  185. Philippou Y, et al. Comparative Oncologic and Toxicity Outcomes of Salvage Radical Prostatectomy Versus Nonsurgical Therapies for Radiorecurrent Prostate Cancer: A Meta-Regression Analysis. Eur Urol Focus. 2016;2:158.
  186. Chade DC, et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol. 2012;61:961.
  187. Michalski J, Pisansky TM, Lawton CA, et al. Prostate cancer. Eds. Gunderson LL, et al. Clinical radiation oncology. Third ed. Philadelphia: Elsevier saunders, 2012; p. 1037-97.
  188. Nilsson S, Norlén BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncologica. 2004;43(4):316-81.
  189. Morris DE, Emami B, Mauch PM, et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: An ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys. 2005;62(1):3-19. doi: 10.1016/j.ijrobp.2004.07.666
  190. Perez CA. Prostate. In: Principles and Practice of Radiation Oncology (3rd ed.). CA Perez, LW Brady (eds.). Lippincott, Philadelphia, 1998; p. 1583-694.
  191. D’Amico AV, Whittington R, Malkovicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-74.
  192. Perez & Brady’s. Principles and Practice of Radiation Oncology (seventh edition). Eds. EC Halperin, DE Wazer, CA Perez, LW Brady. Wolters Kluwer, Philadelphia, 2019; p. 1560-622.
  193. Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056-63.
  194. Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464-73.
  195. Heemsbergen WD, Al-Mamgani A, Slot A, et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110(1):104-9.
  196. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Аnderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67-74.
  197. Kalbasi A, Li J, Berman AT, et al. Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol. 2015;1(7):897-906.
  198. Michalski JM, Moughan J, Purdy J. A randomized trial of 79.2 Gy versus 70.2 Gy radiation therapy (RT) for localized prostate cancer. J Clin Oncol. 2015;33(Suppl.7, abstr.4).
  199. Yu T, et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: A meta-analysis of the literatures. PloS One. 2016;11:5e0154499.
  200. Хмелевский Е.В. Рак предстательной железы. В кн.: Стандарты лучевой терапии. Под ред. А.Д. Каприна, А.А. Костина, Е.В. Хмелевского. М.: ГЭОТАР-Медиа, 2019; с. 191-201 [Khmelevskii EV. Rak predstatel’noi zhelezy. In: Standarty luchevoi terapii. Ed. AD Kaprin, AA Kostin, E.V. Khmelevskiy. Moscow: GEOTAR-Media, 2019; p. 191-201 (in Russian)].
  201. Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74(2):383-7.
  202. Harris V, Staffurs J, Esmail A, et al. Consensus Guidelines and Contouring Atlas for pelvis node delineation in prostate and pelvis node Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015;92:874-83.
  203. Marks LB, Ten Haken RK, Martel MK. Guest editor»s introduction to QUANTEC: a users guide. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl.):S1-2.
  204. Количественный анализ повреждений здоровых органов и тканей при проведении лучевой терапии злокачественных новообразований (проект QUANTEС). Обзор толерантности нормальных тканей. Пер. с англ. Под общ. ред. С.И. Ткачева. М.: АМФР, 2015 [Quantitative analysis of damage to healthy organs and tissues during radiation therapy of malignant neoplasms (QUANTEC project). Review of the tolerance of normal tissues. Trans. from English, Ed. SI Tkachev. Moscow: AMFR, 2015 (in Russian)].
  205. Gay HA, Barthold HJ, O»Meara E, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012;83(3):e353-362.
  206. Cox JD, Stetz JA, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-6.
  207. Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860-8.
  208. Arcangeli S, Strigari L, Gomellini S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1172-8.
  209. Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17(8):1061-9.
  210. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non- inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047-60.
  211. Lee WR, Dignam JJ, Amin MB, et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2016;34(20):2325-32.
  212. Seider MJ, et al. Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Ann Nucl Med. 2018;32(8):553-60. doi: 10.1007/s12149-018-1278-4
  213. Rutter CE, Yu JB, Wilson LD, Park HS. Assessment of national practice for palliative radiation therapy for bone metastases suggests marked underutilization of single-fraction regimens in the United States. Int J Radiat Oncol Biol Phys. 2015;91(3):548-55.
  214. Boyer MJ, Salama JK, Lee WR. Palliative radiotherapy for prostate cancer. Oncology (Williston Park). 2014;28(4):306-12.
  215. Merrick G, Butler W, Lief J, Dorsey A. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;47:121-8.
  216. Wallner K, Lee H, Wasserman S, Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys. 1997;37(3):565–9.
  217. Hughes S, Wallner K, Merrick G, et al. Preexisting histologic evidence of prostatitis is unrelated to postimplant urinary morbidity. Int J Cancer. 2001;96(Suppl.):79-82.
  218. Новиков С.Н., Ощепков В.Н., Канаев С.В., и др. Рекомендации по лечению рака предстательной железы с помощью высокомощностной внутритканевой лучевой терапии (брахитерапии). Экспертное совещание, 17 ноября 2016, Москва. Экспериментальная и клиническая урология. 2017;3:10-23 [Novikov SN, Oshchepkov VN, Kanaev SV, et al. Rekomendatsii po lecheniiu raka predstatel’noi zhelezy s pomoshch’iu vysokomoshchnostnoi vnutritkanevoi luchevoi terapii (brakhiterapii). Ekspertnoe soveshchanie, 17 noiabria 2016, Moskva. Eksperimental’naia i klinicheskaia urologiia. 2017;3:10-23 (in Russian)].
  219. Grann A, Wallner K. Prostate brachytherapy in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 1998;40(1):135-8.
  220. Merrick GS, Butler WM, Wallner KE, et al. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology. 2004;64(4):754-9.
  221. Implementation of High Dose Rate Brachytherapy in Limited Resource Settings. IAEA, 2015.
  222. Kollmeier MA, McBride S, Taggar A, et al. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time. Brachytherapy. 2017;16(6):1091-8. doi: 10.1016/j.brachy.2017.07.013
  223. Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017;71(4):630-42. doi: 10.1016/j.eururo.2016.08.002
  224. James ND, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67:1028.
  225. Glass TR, et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169:164.
  226. Gravis G, et al. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. Eur Urol. 2015;68:196.
  227. Gravis G, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. Eur Urol. 2016;70:256.
  228. Sweeney CJ, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373:737.
  229. Hussain M, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984.
  230. Pagliarulo V, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2012;61:11.
  231. Seidenfeld J, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132(7):566-77.
  232. Kunath F, et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev. 2014;6:CD009266.
  233. Albertsen PC, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65(3):565-73.
  234. Margel D, et al. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease. J Urol. 2019;202(6):1199-208. doi: 10.1097/JU.0000000000000384
  235. ClinicalTrials.gov Identifier: NCT02663908. Available at: https://clinicaltrials.gov/ct2/show/NCT02663908?term= NCT02663908&draw=2&rank=1
  236. Schroder FH, et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2010;106(2):182-7.
  237. Hosseini SA, et al. Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis. Med J Islam Republic Iran. 2016;30:317.
  238. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet. 2000;355:1491.
  239. Schmitt B, et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev. 2000:CD001526.
  240. Akaza H, et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009;115:3437.
  241. Rydzewska LHM, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;84:88-101.
  242. Niraula S, et al. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol. 2013;31:2029.
  243. Sciarra A, et al. A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy? Eur Urol. 2014;65:905.
  244. Botrel TE, et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol. 2014;14:9.
  245. Brungs D, et al. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17:105.
  246. Magnan S, et al. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer A Systematic Review and Meta-analysis. JAMA Oncol. 2015;1:1261.
  247. Hussain M, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314.
  248. Hussain M, et al. Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. J Clin Oncol. 2016;34:280.
  249. Verhagen PC, et al. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial. World J Urol. 2014;32:1287.
  250. Calais da Silva F, et al. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Eur Urol. 2014;66:232.
  251. Abrahamsson P.A. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010;57:49.
  252. Harshman LC, et al. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018;36:376.
  253. Nair B, et al. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. 2002:CD003506.
  254. Eisenberger MA, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036.
  255. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet. 2000;355:1491.
  256. Schmitt B, et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev. 2000:CD001526.
  257. Akaza H, et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009;115:3437.
  258. James ND, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017;377:338.
  259. Fizazi K, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377:352.
  260. James ND, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163.
  261. Gravis G, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149.
  262. Smith TJ, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199.
  263. Sydes MR, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29:1235.
  264. Wallis CJD, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. 2018;73:834.
  265. Sun G, et al. What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. Urologic Oncology: Seminars and Original Investigations. Elsevier. 2018;36(12):505-17.
  266. Chi KN, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381:13-24.
  267. Armstrong AJ, et al. Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. J Clin Oncol. 2019;37(7):687.
  268. Davis ID, Martin AJ, Stockler MR. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121-31. doi: 10.1056/NEJMoa1903835
  269. Boeve LMS, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2018;S0302:30658.
  270. Ost P, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2018;36:446.
  271. Ost P, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67:852.
  272. Crnalic S, et al. Early diagnosis and treatment is crucial for neurological recovery after surgery for metastatic spinal cord compression in prostate cancer. Acta Oncol. 2013;52(4):809-15. doi: 10.3109/0284186X.2012.705437
  273. Boevé LMS, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75(3):410-8. doi: 10.1016/j.eururo.2018.09.008
  274. Heidenreich A, Fossati N, Pfister D, et al. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. Eur Urol Oncol. 2018;1(1):46-53. doi: 10.1016/j.euo.2018.03.002
  275. Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228.
  276. Smith MR, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918.
  277. Smith MR, et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011;117:2077.
  278. Hussain M, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018;378:2465.
  279. Smith MR, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018;378:1408.
  280. Mateo J, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2019;75(2):285-93. doi: 10.1016/j.eururo.2018.07.035
  281. Hussain M, et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol. 1994;12:1868.
  282. Taylor CD, et al. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:2167.
  283. Ryan CJ, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138.
  284. Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152.
  285. Roviello G, et al. Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials. Medicine (Baltimore). 2016;95:e4636.
  286. Shore ND, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17:153.
  287. Beer TM, et al. Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017;71:151.
  288. Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424.
  289. Graff JN, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016;27:286.
  290. Evans CP, et al. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016;70:675.
  291. Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502.
  292. Kellokumpu-Lehtinen PL, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14:117.
  293. Scher HI, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402.
  294. Armstrong AJ, et al. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010;16:203.
  295. Italiano A, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol. 2009;55:1368.
  296. Horgan AM, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate- resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol. 2014;5:119.
  297. De Bono JS, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration- resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147.
  298. Scher HI, et al. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst. 1996;88:1623.
  299. Sartor A, et al. Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). J Clin Oncol. 2016;34:Abstract5006.
  300. Eisenberger M, et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol. 2017;35:3198.
  301. Resnick MJ, et al. Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. J Clin Oncol. 2015;33:1078.
  302. Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213.
  303. Hoskin P, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397.
  304. Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5
  305. Smith MR, et al. ERA 223: A phase 3 trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with mCRPC. ESMO Congress Oct 19-23, 2018, Munich, Germany; 2018.
  306. De Bono JS, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995.
  307. Fizazi K, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983.
  308. Scher HI, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187.
  309. De Bono JS, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017;71:656.
  310. Badrising S, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer. 2014;120:968.
  311. Zhang T, et al. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Expert Opin Pharmacother. 2015;16:473.
  312. Antonarakis ES, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028.
  313. Attard G, et al. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. J Clin Oncol. 2018;36:2639.
  314. De Bono J, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. N Engl J Med. 2020;382:2091-102. doi: 10.1056/NEJMoa1911440
  315. LYNPARZA (olaparib) US prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.
  316. De Bono et al. PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Presented at ASCO GU 2020 13th–15th February. San Francisco, CA. Poster F14.
  317. Rexer H, et al. Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)-study AP 93/16 of the AUO. Urologe A. 2017;56(11):1471-2. doi: 10.1007/s00120-017-0519-9
  318. Gillessen S, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26:1589.
  319. Aggarwal R, et al. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018;1:78.
  320. Payne H, et al. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol. 2011;29:593.
  321. Pezaro CJ, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65:270.
  322. Ohlmann C, et al. Second-line chemotherapy with docetaxel for prostate-specific antigen relapse in men with hormone refractory prostate cancer previously treated with docetaxel based chemotherapy. Eur Urol. 2006;5:abstract #289.
  323. Gillessen S, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73:178.
  324. Esper PS, et al. Supportive care in the patient with hormone refractory prostate cancer. Semin Urol Oncol. 1997;15:56.
  325. Белозерова М.С., Кочетова Т.Ю., Крылов В.В. Практические рекомендации по радионуклидной терапии при метастазах в кости. Злокачественные опухоли. 2015;4(Спецвып.):448-54 [Belozerova MS, Kochetova TIu, Krylov VV. Prakticheskie rekomendatsii po radionuklidnoi terapii pri metastazakh v kosti. Zlokachestvennye opukholi. 2015;4(Spetsvyp.):448-54 (in Russian)]. doi: 10.18027/2224-5057-2015-4s-448-454
  326. Handkiewicz-Junak D, Poeppel TD, Bodei L, et al. EANM Guidelines for Radionuclide Therapy of Bone Metastases With Beta-Emitting Radionuclides. Eur J Nucl Med Mol Imaging. 2018;45(5):846-59. doi: 10.1007/s00259-018-3947-x
  327. Крылов В.В., Кочетова Т.Ю., Волознев Л.В. Радионуклидная терапия при метастазах в кости: новые возможности. Вопросы онкологии. 2015;61(1):14-9 [Krylov VV, Kochetova TIu, Voloznev LV. Radionuklidnaia terapiia pri metastazakh v kosti: novye vozmozhnosti. Voprosy onkologii. 2015;61(1):14-9 (in Russian)].
  328. Крылов В.В., Кочетова Т.Ю., Белозерова М.С., Волознев Л.В. Особенности применения различных радиофармпрепаратов при метастазах в кости. Паллиативная медицина и реабилитация. 2015;4:26-33 [Krylov VV, Kochetova TIu, Belozerova MS, Voloznev LV. Osobennosti primeneniia razlichnykh radiofarmpreparatov pri metastazakh v kosti. Palliativnaia meditsina i reabilitatsiia. 2015;4:26-33 (in Russian)].
  329. Pagliarulo V, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2012;61:11.
  330. Крылов В.В., Дроздовский Б.Я., Карякин О.Б., и др. Радионуклидная терапия самарием, 153Sm оксабифором у больных раком предстательной железы с метастазами в кости. Онкоурология. 2007;1:53-8 [Krylov VV, Drozdovskii BIa, Kariakin OB, et al. Radionuklidnaia terapiia samariem, 153Sm oksabiforom u bol’nykh rakom predstatel’noi zhelezy s metastazami v kosti. Onkourologiia. 2007;1:53-8 (in Russian)].
  331. Dy SM, et al. Evidence-based standards for cancer pain management. J Clin Oncol. 2008;26:3879.
  332. Hartsell WF, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97:798.
  333. Hoskin P, et al. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer. J Natl Cancer Inst. 2015;107.
  334. Frankel BM, et al. Percutaneous vertebral augmentation: an elevation in adjacent-level fracture risk in kyphoplasty as compared with vertebroplasty. Spine J. 2007;7:575.
  335. Dutka J, et al. Time of survival and quality of life of the patients operatively treated due to pathological fractures due to bone metastases. Ortop Traumatol Rehabil. 2003;5:276.
  336. Frankel BM, et al. Segmental polymethylmethacrylate-augmented pedicle screw fixation in patients with bone softening caused by osteoporosis and metastatic tumor involvement: a clinical evaluation. Neurosurgery. 2007;61:531.
  337. Marco RA, et al. Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am. 2000;82:642.
  338. Saad F, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458.
  339. Fizazi K, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813.
  340. Smith MR. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-55.
  341. Smith MR, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39.
  342. Stopeck AT, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24:447.
  343. Aapro M, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19:420.
  344. Medication-Related Osteonecrosis of the Jaws, S. Otto, Editor. 2015, Springer-Verlag Berlin Heidelberg.
  345. Westhoff PG, et al. Quality of life in relation to pain response to radiation therapy for painful bone metastases. Int J Radiat Oncol Biol Phys. 2015;93(3):694-701.
  346. Lane JA, et al. ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. Cancer Prev Res (Phila). 2018;11(11):687-96. doi: 10.1158/1940-6207.CAPR-18-0147
  347. Resnick MJ, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436.
  348. Barocas DA, et al. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. JAMA. 2017;317:1126.
  349. Santa Mina D, et al. A pilot randomized trial of conventional versus advanced pelvic floor exercises to treat urinary incontinence after radical prostatectomy: a study protocol. BMC Urol. 2015;15:94. doi: 10.1186/s12894-015-0088-4
  350. Aydýn Sayýlan A, Özbaþ A. The effect of pelvic floor muscle training on incontinence problems after radical prostatectomy. Am J Mens Health. 2018;12(4):1007-15.
  351. Anderson CA, et al. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev. 2015;1:CD001843.
  352. Chen YC, et al. Surgical treatment for urinary incontinence after prostatectomy: A meta- analysis and systematic review. PLoS One. 2017;12:e0130867.
  353. Pavlovich CP, et al. Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. BJU Int 2013;112:844.
  354. Philippou YA, et al. Penile rehabilitation for postprostatectomy erectile dysfunction. Cochrane Database Syst Rev. 2018;10:CD012414.
  355. Dieperink KB, et al. The effects of multidisciplinary rehabilitation: RePCa-a randomised study among primary prostate cancer patients. Br J Cancer. 2013;109:3005.
  356. Buffart LM, et al. The effect, moderators, and mediators of resistance and aerobic exercise on health‐related quality of life in older long‐term survivors of prostate cancer. Cancer. 2015;121(16):2821-30.
  357. Silver JA, Baima J. Cancer prehabilitation: an opportunity to decrease treatment related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil. 2013;92:715-27.
  358. Tsimopoulou I, Pasquali S, Howard R, et al. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review. Ann Surg Oncol. 2015;22(13):4117-23. doi: 10.1245/s10434-015-4550-z
  359. Azhar RA, Bochner B, Catto J, et al. Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs. Eur Urol. 2016;70(1):176-87.
  360. Baguley BJ, et al. The effect of nutrition therapy and exercise on cancer-related fatigue and quality of life in men with prostate cancer: a systematic review. Nutrients. 2017;9(9):1003.
  361. Hulzebos EH, Helders PJ, Favie NJ, et al. Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery: a randomized clinical trial. JAMA. 2006;296(15):1851-7.
  362. Swarm R, Abernethy AP, Anghelescu DL, et al; NCCN Adult Cancer Pain. Adult cancer pain. J Natl Compr Canc Netw. 2010;8:1046-86.
  363. Lin C, Wan F, Lu Y, et al. Enhanced recovery after surgery protocol for prostate cancer patients undergoing laparoscopic radical prostatectomy. J Int Med Res. 2018;47(1):114-21.
  364. Shin KY, Guo Y, Konzen B, et al. Inpatient cancer rehabilitation: the experience of a national comprehensive cancer center. Am J Phys Med Rehabil. 2011;90(5):63-S68.
  365. Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75(3):410-8. doi: 10.1016/j.eururo.2018.09.008
  366. Bourke L, Homer KE, Thaha MA, et al. Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review. Br J Cancer. 2014;110:831-41.
  367. Hunter EG, Baltisberger J. Functional outcomes by age for inpatient cancer rehabilitation: a retrospective chart review. J Appl Gerontol. 2013;32(4): 443-56.
  368. Frisk J, et al. Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer – a prospective multicenter study with long-term follow-up. Eur Urol. 2009;55(1):156-63.
  369. Segal R, Zwaal C, Green E, et al. Exercise for People with Cancer Guideline Development G: Exercise for people with cancer: a systematic review. Curr Oncol. 2017;24(4):e290-e315.
  370. Boyd C, Crawford C, Paat CF, et al. Evidence for Massage Therapy Working G: The Impact of Massage Therapy on Function in Pain Populations-A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part II, Cancer Pain Populations. Pain Med. 2016;17(8):1553-68.
  371. Mehling WE, Jacobs B, Acree M, et al. Symptom management with massage and acupuncture in postoperative cancer patients: a randomized controlled trial. J Pain Symptom Manage. 2007;33(3):258-66.
  372. Kessels E, Husson O, van der Feltz-Cornelis CM. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2018;14:4790-94.
  373. Rief H, Omlor G, Akbar M, et al. Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy – first results of a randomized pilot trial. BMC Cancer. 2014;14:67.
  374. Bensadoun RJ, Nair RG. Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy. Photomed Laser Surg. 2015;33(10):487-91.
  375. Shen S, et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol. 2005;173:777.
  376. Teeter AE, et al. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. J Urol. 2018;199:713.
  377. Stephenson AJ, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973.
  378. Loblaw A, et al. Follow-up care for survivors of prostate cancer–clinical management: a program in evidence-based care systematic review and clinical practice guideline. Clin Oncol. 2017;29(11):711-7.
  379. Horwitz EM, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol. 2005;173:797.
  380. Oefelein MG, et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol. 1995;154:2128.
  381. Tokas T, et al. A 12-year follow-up of ANNA/C-TRUS image-targeted biopsies in patients suspicious for prostate cancer. World J Urol. 2018;36(5):699-704.
  382. Barry MJ, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-57.
  383. Cockett ATK, et al. Recommendations of the International Consensus Committee concerning Prostate Symptom Score (IPSS) and Quality of Life Assessment; in The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Patronized by WHO. SCI 1994, pp. 553-55.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.

Download (139KB)
Indexing metadata

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies